Drug Development in Pemphigoid Diseases.

Drug Development in Pemphigoid Diseases.
Acta Derm Venereol. 2020 Feb 06;:
Authors: Bieber K, Ludwig RJ
Abstract
Pemphigoid diseases are organ-specific autoimmune diseases of the skin and/or mucous membranes. They are caused by autoantibodies targeting adhesion molecules located at the dermal-epidermal junction. While the diagnostics of pemphigoid diseases and insights into their pathogenesis have improved significantly, the development of novel treatments that are effective and safe remains an unmet medical need. However, numerous pre-clinical studies and early clinical trials have recently been launched. This review summarizes some pathways leading to drug development in pemphigoid diseases, namely: (i) hypothesis-driven drug development; (ii) omics-based drug development; (iii) drug repurposing; (iv) screening-based drug development; and (v) drug development based on careful clinical observations. Ultimately, it is hoped that this will lead to personalized and curative treatments.
PMID: 32039458 [PubMed - as supplied by publisher]

Source: Acta Dermato-Venereologica - February 5, 2020 Category: Dermatology Authors: Bieber K, Ludwig RJ Tags: Acta Derm Venereol Source Type: research